Table 1.
Baseline characteristics (n = 843)
| Characteristic | Patients, n (%) |
|---|---|
| Gender | |
| Male | 490 (58.1) |
| Female | 353 (41.9) |
| Age at start of erlotinib treatment | |
| <65 years | 416 (49.3) |
| ≥65 years | 427 (50.7) |
| Histological type | |
| Adenocarcinoma | 631 (74.9) |
| Other | 12 (1.4) |
| Unknown | 200 (23.7) |
| Stage of pancreatic cancer | |
| Postoperative recurrence | 83 (9.8) |
| IVa | 154 (18.3) |
| IVb | 594 (70.5) |
| Other | 5 (0.6) |
| Unknown | 7 (0.8) |
| Site of primary tumor | |
| Head of pancreas | 348 (41.3) |
| Body of pancreas | 329 (39.0) |
| Tail of pancreas | 200 (23.7) |
| Other | 7 (0.8) |
| Metastases | |
| No | 137 (16.3) |
| Yes | 704 (83.5) |
| Unknown | 2 (0.2) |
| Site of metastatic foci | |
| Liver | 448 (63.6) |
| Peritoneal | 165 (23.4) |
| Lymph node | 263 (37.4) |
| Lung | 118 (16.8) |
| Bone | 28 (4.0) |
| Brain | 2 (0.3) |
| Other | 37 (5.3) |
| Previous or concurrent lung disease | |
| Lung infection: No | 805 (95.5) |
| Lung infection: Yes | 31 (3.7) |
| Unknown | 7 (0.8) |
| ILD: No | 833 (98.8) |
| ILD: Yes | 3 (0.4) |
| Unknown | 7 (0.8) |
| Lung emphysema or COPD: No | 816 (96.8) |
| Lung emphysema or COPD: Yes | 20 (2.4) |
| Unknown | 7 (0.8) |
| Asthma: No | 819 (97.2) |
| Asthma: Yes | 18 (2.1) |
| Unknown | 6 (0.7) |
| Tuberculosis: No | 826 (98.0) |
| Tuberculosis: Yes | 10 (1.2) |
| Unknown | 7 (0.8) |
| Smoking history | |
| No | 467 (55.4) |
| Yes | 372 (44.1) |
| Current smoker | 56 (15.0) |
| Past smoker | 313 (84.1) |
| Unknown | 3 (0.8) |
| Unknown | 4 (0.5) |
| ECOG PS | |
| 0 | 583 (69.2) |
| 1 | 251 (29.8) |
| 2 | 7 (0.8) |
| Unknown | 2 (0.2) |
COPD, chronic obstructive pulmonary disease; ECOG PS, Eastern Cooperative Oncology Group performance status; ILD, interstitial lung disease.